Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

NervGen Pharma (9UA) Stock Price & Analysis

3 Followers

9UA Stock Chart & Stats

€1.25€0.04(3.31%)
At close: 5:30 PM GMT+1
€1.25€1.5€1.75Aug 6Aug 26Sep 14Sep 17Oct 5Oct 23Nov 2
Day’s Range
EUR 1.25 - EUR 1.39
52-Week Range
EUR 1.21 - EUR 5.00
Previous Close
EUR 1.21
Volume
N/A
Average Volume (3M)
709
Market Cap
EUR 129.25M
Enterprise Value
EUR 155.34M
Total Cash (Recent Filing)
EUR 86.93M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
0.48
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-0.09
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Financial Leverage

Near-zero debt reduces fixed financial obligations and preserves flexibility to direct capital toward clinical development. The increase in assets to about $90.3M indicates stronger capitalization than 2025, although it does not eliminate the need for future funding.

Improved Cash Position

The substantial increase in cash provides a larger funding base for ongoing research, clinical trials, and corporate operations over the next several quarters. This strengthens near-term execution capacity, even though continued losses mean the cash position may require replenishment.

Focused Neurological Pipeline

A focused development strategy around nerve repair and regeneration gives NervGen a clear therapeutic identity and concentrates resources on a lead asset. Broader neurological applications could expand the opportunity if clinical development establishes useful activity across indications.

Bears Say

Pre-Revenue Business Model

With no product revenue, NervGen cannot currently fund operations through recurring commercial sales and remains dependent on development progress and external capital. This leaves financial performance highly exposed to clinical timelines, regulatory outcomes, and financing conditions.

Accelerating Cash Burn

Operating cash outflows are increasing as research and development activities continue, reducing the duration of existing resources and increasing reliance on future financing. Persistent negative free cash flow also limits internally funded investment and raises execution pressure.

Financial Reporting Restatement

Restating multiple annual and interim periods signals weaknesses in accounting processes and internal controls, which can undermine confidence in reported results. Although the errors are non-cash and liquidity is unaffected, remediation may add oversight burdens and reporting uncertainty.

NervGen Pharma News

9UA FAQ

What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was €1.21 and its highest was €5.00 in the past 12 months.
What is NervGen Pharma’s market cap?
NervGen Pharma’s market cap is €129.25M.
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is in 8 days.
How were NervGen Pharma’s earnings last quarter?
NervGen Pharma released its earnings results on Aug 13, 2026. The company reported -€0.236 earnings per share for the quarter, missing the consensus estimate of -€0.054 by -€0.181.
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate is -0.09.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 107,616,410 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
NervGen Pharma reported an EPS of -€0.236 in its last earnings report, missing expectations of -€0.054. Following the earnings report the stock price went up 2.837%.
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in DE:9UA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology